Intellia Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
NTLA$11.17-7.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||
| Net loss | $(481,192) | $(474,186) | $(267,892) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 8,976 | 7,572 | 6,891 |
| Loss (gain) on disposal of property and equipment | 72 | (162) | - |
| Stock-based compensation | 134,050 | 91,400 | 47,009 |
| (Accretion) amortization of investment discounts and premiums | (25,897) | 4,003 | 7,604 |
| Loss from equity method investment | 15,633 | 11,079 | 1,325 |
| Deferral of equity method investment intra-entity profit on sales | 6,624 | 11,405 | 2,937 |
| Change in fair value of contingent consideration | 100 | 13,485 | - |
| In-process research and development expense | - | 55,990 | - |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | (32,688) | (1,737) | 99 |
| Prepaid expenses and other current assets | (27,168) | (2,160) | (9,798) |
| Operating lease right-of-use assets | 19,011 | 13,121 | 9,349 |
| Other assets | (707) | (1,091) | 117 |
| Accounts payable | 2,522 | (4,584) | 529 |
| Accrued expenses | 6,024 | 15,924 | 17,260 |
| Deferred revenue | (2,778) | (63,464) | (31,355) |
| Operating lease liabilities | (16,668) | (9,882) | (9,105) |
| Net cash used in operating activities | (394,086) | (333,287) | (225,030) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||
| Purchases of property and equipment | (13,985) | (13,558) | (12,756) |
| Purchases of marketable securities | (904,464) | (429,032) | (1,020,620) |
| Maturities of marketable securities | 887,102 | 647,581 | 485,598 |
| Proceeds from sale of property and equipment | - | 150 | - |
| Acquired in-process research and development, net of cash acquired of $287 | - | (44,832) | - |
| Investment in Kyverna Therapeutics, Inc. | - | - | (3,000) |
| Net cash (used in) provided by investing activities | (31,347) | 160,309 | (550,778) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||
| Net proceeds from issuance of common stock through follow-on offerings, net of issuance costs | - | 337,892 | 648,315 |
| Net proceeds from issuance of common stock through at-the-market offerings, net of issuance costs | 119,795 | 227,897 | 45,255 |
| Proceeds from options exercised | 6,599 | 14,517 | 41,094 |
| Issuance of shares through employee stock purchase plan | 3,929 | 2,649 | 2,024 |
| Net cash provided by financing activities | 130,323 | 582,955 | 736,688 |
| Net (decrease) increase in cash and cash equivalents and restricted cash equivalents | (295,110) | 409,977 | (39,120) |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | 535,463 | 125,486 | 164,606 |
| Cash, cash equivalents and restricted cash equivalents, end of period | $240,353 | $535,463 | $125,486 |
| Reconciliation of cash, cash equivalents and restricted cash equivalents to consolidated balance sheet: | |||
| Cash and cash equivalents | $226,748 | $523,506 | $123,406 |
| Restricted cash equivalents, included in investments and other assets | 13,605 | 11,957 | 2,080 |
| Total cash, cash equivalents and restricted cash equivalents | $240,353 | $535,463 | $125,486 |
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: | |||
| Purchases of property and equipment unpaid at period end | $1,525 | $1,623 | $667 |
| Shares issued for Rewrite contingent consideration | 24,126 | - | - |
| Right-of-use assets acquired under operating leases | 1,311 | 67,053 | 49,378 |
| Proceeds from at-the-market offerings unpaid at period end | 2,075 | - | - |
| Contingent consideration liability assumed in asset acquisition | - | 10,541 | - |
| Non-cash trade-in of property and equipment | - | 200 | - |
| Non-cash contribution of intellectual property to AvenCell Therapeutics, Inc. | - | - | 62,900 |
| Non-cash contribution of intellectual property to SparingVision SAS | - | - | 14,759 |
| Non-cash contribution of intellectual property to Kyverna Therapeutics, Inc. | - | - | 7,000 |
| The accompanying notes are an integral part of these consolidated financial statements. | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.